Literature DB >> 22814872

Marinobufagenin predicts and resibufogenin prevents preeclampsia: a review of the evidence.

Jules B Puschett1.   

Abstract

OBJECTIVE: The purpose of this review is to provide information detailing the existing evidence with regard to the hypothesis that marinobufagenin (MBG) is an important etiologic and predictive factor in preeclampsia (PE). In addition, evidence describing the role of the antagonist to MBG, resibufogenin (RBG), in the prevention and/or treatment of this disorder is provided. STUDY
DESIGN: The studies outlined were performed in an animal model of PE, in in vitro experiments, and in human studies.
RESULTS: Data have been obtained that strongly support the hypothesis that ~60 to 70% of PE patients demonstrate elevations in urinary and serum MBG levels. In the animal model, the entire syndrome can be prevented by the administration of RBG beginning early in pregnancy.
CONCLUSION: Expanded human trials of MBG as a predictor of the later development of PE are warranted as are studies of the efficacy and safety of RBG as a preventative/therapy. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814872     DOI: 10.1055/s-0032-1316447

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  2 in total

1.  Involvement of the Bufadienolides in the Detection and Therapy of the Acute Respiratory Distress Syndrome.

Authors:  Mir M K Abbas; B Patel; Q Chen; W Jiang; B Moorthy; R Barrios; J B Puschett
Journal:  Lung       Date:  2017-03-04       Impact factor: 2.584

2.  Comparison of Neurocognitive Testing and the Measurement of Marinobufagenin in Mild Traumatic Brain Injury: A Preliminary Report.

Authors:  Joel Oliver; Kamran Abbas; J Timothy Lightfoot; Kelly Baskin; Blaise Collins; David Wier; Joe P Bramhall; Jason Huang; Jules B Puschett
Journal:  J Exp Neurosci       Date:  2015-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.